Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)

Advances in Therapy

Volumn 33, Issue 7, 2016, Pages 1140-1157

  Otake, Kazuyoshi ^a   Sakurai, Yuuichi ^a   Nishida, Haruyuki ^a   Fukui, Hideo ^a   Tagawa, Yoshihiko ^a   Yamasaki, Hitomi ^a   Karashima, Masatoshi ^a   Otsuka, Keiichi ^a   Inatomi, Nobuhiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Acid related diseases; Gastroenterology; Helicobacter pylori eradication; Lansoprazole; Potassium competitive acid blockers; PPI; Proton pump inhibitor; Reflux esophagitis; TAK 438; Vonoprazan

Indexed keywords

FUMARIC ACID DERIVATIVE; LANSOPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; VONOPRAZAN FUMARATE; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; GASTROINTESTINAL AGENT; PYRROLE DERIVATIVE; SULFONAMIDE;

AREA UNDER THE CURVE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; STOMACH DISEASE; GASTROINTESTINAL DISEASES; PH;

GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; HYDROGEN-ION CONCENTRATION; PYRROLES; SULFONAMIDES;

EID: 84973598622     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0345-2     Document Type: Review

References (66)

1. Huang JQ, Hunt RH. pH, healing rate and symptomatic relief in acid-related diseases. Yale J Biol Med. 1996;69:159–74.
2. Hirschowitz BI, Keeling D, Lewin M, et al. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995;40(2 Suppl):3S–23S.
3. Urushidani T, Nagao T. Calyculin A, a phosphoprotein phosphatase inhibitor, stimulates acid secretion in isolated gastric glands. Am J Physiol. 1996;270(1 Pt 1):G103–12.
4. +-stimulated pNPPase. Gastroenterology. 1975;69:175–89.
5. Chow DC, Forte JG. Functional significance of the beta-subunit for heterodimeric P-type ATPases. J Exp Biol. 1995;198:1–17.
6. Rabon E, Cuppoletti J, Malinowska D, et al. Proton secretion by the gastric parietal cell. J Exp Biol. 1983;106:119–33.
7. + ATPase in human tissue. Scand J Gastroenterol. 2007;42:1275–88.
8. +-ATPase isoforms in human kidney. Am J Physiol Renal Physiol. 2001;281(4):F763–8.
9. Forte JG, Hanzel DK, Okamoto C, Chow D, Urushidani T. Membrane and protein recycling associated with gastric HCl secretion. J Intern Med Suppl. 1990;732:17–26.
10. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 1994;201:79–82.
11. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59–67.
12. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159:649–57.
13. Mössner J, Caca K. Developments in the inhibition of gastric acid secretion. Eur J Clin Invest. 2005;35:469–75.
14. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med. 1996;69:301–16.
15. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of H. pylori infections: 2009 revised edition. Helicobacter. 2010;15:1–20.
16. Yuan Y, Wang CC, Yuan YH, et al. The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology. 2008;134(Suppl 1):A174.
17. Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Trans Gastroenterol. 2015;6:e119. doi:10.1038/ctg.2015.39.
18. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol. 2008;8(6):677–84.
19. Tytgat GN. Are there unmet needs in acid suppression? Best Pract Res Clin Gastroenterol. 2004;18(Suppl):67–72.
20. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther. 2005;22(2):79–94.
21. Japanese Society for Gastroenterology. Guidelines for the management of GERD (2009). http://minds4.jcqhc.or.jp/minds/GERD/gerd_gl.pdf.
22. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–84.
23. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.
24. Ashida K. Notes on features and uses of medications used for PPI-resistant GERD, drugs under development and future prospects. Jpn J Med Pharm Sci. 2014;71:591–6.
25. +)-ATPase. J Biol Chem. 1981;256:2682–90.
26. +-ATPase. J Biol Chem. 1990;265:5030–6.
27. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005;14:411–21.
28. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:1385–91.
29. Berg AL, Böttcher G, Andersson K, et al. Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor. Toxicol Pathol. 2008;36:727–37.
30. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20–6.
31. Kondo M, Kawamoto M, Hasuoka A, et al. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177–82.
32. Nishida H, Hasuoka A, Arikawa Y, et al. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg Med Chem. 2012;20:3925–38.
33. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446–56.
34. Takeda Takecab (vonoprazan tablets). Japanese Common Technical Document. Available at: http://www.pmda.go.jp/drugs/2014/P201400173/index.html. Accessed 20 Apr 2016.
35. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–51.
36. Mizokami Y, Ashida K, Soen S, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial. Gastroenterology. 2014;146(5,Suppl 1):S-739.
37. Kawai T, Ashida K, Mizokami Y, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial. Gastroenterology. 2014;146(5,Suppl 1):S-739.
38. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016. doi:10.1136/gutjnl-2015-311304 (Epub ahead of print).
39. Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797–804.
40. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–8.
41. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14(10):1259–66.
42. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65:552–61.
43. Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther. 2002;16(4):837–46.
44. Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001;36:669–72.
45. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–28.
46. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453–60.
47. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprasole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–59.
48. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;25(6):e94.
49. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636–48.
50. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989;248:799–805.
51. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1–6.
52. +-adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology. 1995;109:1134–41.
53. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol. 2001;13(Suppl 1):S35–41.
54. Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(4):389–98.
55. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2–8.
56. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001;13(Suppl 1):S29–33.
57. Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–20.
58. +-ATPase induced by an acid suppressant. Nat Commun. 2011;2:155–61.
59. Matsukawa J, Hori Y, Nishida H, kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–51.
60. Takeda Takecab (vonoprazan tablets) package insert. Available at: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_2329030F1020_1_04. Accessed 20 Apr 2016.
61. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–72.
62. Wada F, Murase K, Isomoto H, et al. Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers. J Int Med Res. 2002;30:413–21.
63. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006;44:297–302.
64. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294–307.
65. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–47.
66. Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficle-associated diarrhea? J Hosp Infect. 2008;70:1–6.